+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.

Age: 16Years - 80YearsAll GendersPhase 3
499 locations
S

Actively Recruiting

This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.

Age: 55Years +All GendersPhase 4
105 locations
S

Actively Recruiting

Researchers are studying the effects of orticumab treatment on inflammation in people who have had a heart attack and show increased coronary inflammation as seen on coronary computed tomography angiography CCTA. This Phase 2 trial aims to compare the impact of orticumab versus placebo on inflammation in coronary arteries, measured using the Fat Attenuation Index FAI, over a 6-month period. The study focuses on participants with prior myocardial infarction who meet specific inflammation criteria based on CCTA imaging and are on stable cardiovascular treatment. Participants will receive either orticumab or placebo treatment for 24 weeks. There are multiple treatment groups, including high and low doses of both orticumab and placebo. An optional Day 14 sub-study is available where participants can have additional safety assessments and blood tests to measure serum orticumab levels and inflammation biomarkers. Throughout the study, participants are expected to attend all scheduled visits, provide complete medical history, and consult the study doctor before any changes to their usual treatments. During the study, participants will undergo assessments including CCTA scans to measure coronary artery inflammation, blood tests for safety and biomarker analysis, and monitoring for adverse events. The main outcome is the percent change in the mean FAI score in the coronary arteries after 24 weeks of treatment. Secondary outcomes include changes in coronary artery inflammation and CaRi-Heart score. Safety monitoring and adherence to cardiovascular medication regimens will be maintained throughout the trial, which is expected to continue until June 2027.

Age: 18Years +All GendersPhase 2
41 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a new contactless and non-invasive method to measure how the skins tiny blood vessels and their regulatory functions work in both healthy people and those with type 1 diabetes-related microvascular disease. The goal is to find an early way to detect diabetic complications before severe small vessel damage develops. This observational study uses advanced imaging to better understand microangiopathy linked to diabetes. The study uses an investigational device called the TCI P4, which shines patterned light on the skin and captures detailed images to analyze skin structure and molecular makeup, including oxygen and blood content. Measurements from this device will be compared to other established tools like laser speckle contrast imaging and the EPOS system to validate its accuracy. Participants include groups categorized by different severity levels of microvascular complications related to diabetes, as well as healthy controls. Participants will undergo evaluations that measure blood flow responses in the skin, specifically peak perfusion after warming the area and blood flow patterns in the soles of the feet. These assessments happen within one day of enrollment. The study will monitor these microvascular functions to understand their relationship with diabetic damage. Participation involves a single-day visit for these imaging tests. The study is sponsored by Karolinska Institutet and plans to continue until December 2027.

Age: 18Years - 60YearsAll Genders
1 location
R

Actively Recruiting

This trial investigates adults with symptomatic hip osteoarthritis who are eligible for two types of hip replacement surgery ceramic hip resurfacing arthroplasty and total hip arthroplasty. It is a pragmatic, multicenter, randomized clinical trial designed to compare these two procedures in terms of physical activity outcomes, including walking distance. The study aims to determine if ceramic hip resurfacing leads to better walking ability during the first two years after surgery, with additional long-term follow-up planned. Participants are randomly assigned to receive either cementless ceramic-on-ceramic hip resurfacing arthroplasty or contemporary total hip arthroplasty using standard implants suited to their clinical needs. Both procedures are conducted by experienced surgeons following manufacturer and clinical protocols. The trial includes baseline assessments before surgery, followed by wearable activity monitoring at 3, 12, and 24 months postoperatively. An observational cohort is also conducted for patients who decline randomization but meet eligibility. Throughout the study, participants complete patient-reported outcomes, radiographs, and 7-day activity monitoring sessions to evaluate walking distance and other functional measures. Researchers assess various outcomes including daily walking distance, step count, hip function scores, implant survival, complications, and health-economic data. Follow-up visits extend up to 10 years to monitor long-term implant performance and patient activity, with safety and other secondary outcomes tracked regularly.

Age: 18Years +All GendersPhase Not Applicable
1 location
T

Actively Recruiting

Researchers are evaluating the medicine BI 764198 to see if it helps people with certain kidney conditions, including secondary focal segmental glomerulosclerosis, treatment-resistant primary minimal change disease, Alport Syndrome, and treatment-resistant primary membranous nephropathy. The study includes adults and adolescents with specific kidney diseases and aims to assess the medicines safety, tolerability, and effectiveness compared to a placebo. Participants are randomly assigned to one of two groups one group takes BI 764198 tablets and the other takes placebo tablets that look identical but do not contain medicine. They take one tablet daily for 20 weeks while continuing their usual kidney disease treatments. The chance of being assigned to the BI 764198 group is twice as high as being assigned to the placebo group. The study lasts about 7 months, during which participants attend six site visits and three phone calls. Doctors regularly collect urine and blood samples to measure protein levels and kidney function. They monitor health and any side effects, comparing results between the groups to evaluate the treatment. The primary outcome is the change in urine protein-to-creatinine ratio after 20 weeks.

Age: 12Years +All GendersPhase 2
154 locations
R

Actively Recruiting

Researchers are evaluating the effects of a restrictive strategy for giving non-resuscitation fluids to adult patients with septic shock. This trial aims to compare a protocolized reduction of these fluids against usual care to assess both beneficial and harmful impacts on patients during intensive care. The study focuses on adults who meet specific septic shock criteria, including infection suspicion, elevated plasma lactate, and need for vasopressors. Participants are randomly assigned to one of two groups. In the experimental group, non-resuscitation fluids are given according to a strict protocol that starts within two hours of randomization and continues during the ICU stay, up to 90 days. This protocol includes guidelines about maintenance fluids, intravenous and enteral hydration, nutrition, glucose use, and medication concentration. The other group receives fluids according to local standard practices with some general guidelines. Both groups are monitored throughout their ICU admission. During the study, participants undergo regular assessments including survival status at 90 days, complications in the ICU, and number of days free from mechanical ventilation within 90 days. Researchers also evaluate cognitive function and health-related quality of life six months after inclusion. The trial uses triple masking and follows participants from enrollment through ICU discharge and beyond, with the total participation lasting up to several months depending on individual outcomes.

Age: 18Years +All GendersPhase Not Applicable
22 locations
P

Actively Recruiting

Researchers are conducting a phase III trial to evaluate the safety and effectiveness of autologous skeletal muscle-derived cells for patients with urge fecal incontinence caused by dysfunction or damage to the external anal sphincter. This study aims to assess clinical outcomes in patients who have not sufficiently improved with conservative treatments. The condition involves uncontrolled leakage due to sphincter weakness or disruption. Participants receive either injections of their own skeletal muscle-derived cells into the external anal sphincter or a placebo solution. The study is randomized with two groups one receiving the investigational cell therapy and the other receiving the placebo vehicle. Both treatments are administered under medical supervision, and the study follows participants over a 12-month period to assess changes in incontinence episodes. During the trial, participants will be monitored for safety and efficacy through regular evaluations. The main outcome measured is the change in the frequency of incontinence episodes over 12 months. The study includes thorough assessments such as anal manometry and ultrasound imaging of the anal canal. Participants adherence, symptoms, and safety are carefully tracked through scheduled visits throughout the trial duration.

Age: 18Years +All GendersPhase 3
34 locations
P

Actively Recruiting

Researchers are examining the effect of abelacimab compared to a placebo in patients with atrial fibrillation AF who are considered unsuitable for oral anticoagulation therapy. This Phase 3 study focuses on high-risk patients with AF to evaluate whether abelacimab can reduce the occurrence of ischemic stroke or systemic embolism. The study is led by Anthos Therapeutics, Inc. and aims to address treatment options in patients where traditional anticoagulation is deemed inappropriate. Participants are randomly assigned in equal numbers to receive either abelacimab 150 mg or a matching placebo by subcutaneous injection once a month. The study consists of three periods a screening period lasting up to 60 days, a double-blind treatment period that continues until at least 111 patients experience a primary endpoint event, and an end-of-treatment visit. Following this, participants may enter a 30-day follow-up or an optional open-label extension to receive abelacimab, depending on eligibility and regulatory approval. During the study, participants undergo assessments to monitor stroke, systemic embolism, and bleeding events, with the primary outcomes measured up to 30 months. Safety is tracked by recording bleeding events classified by the Bleeding Academic Research Consortium. Secondary outcomes include cardiovascular and all-cause mortality and other thrombotic events. The study also involves regular monitoring and follow-up visits to assess efficacy and safety throughout the treatment and observation periods.

Age: 65Years +All GendersPhase 3
789 locations